Abbott price target lowered to $120 from $145 at Stifel

Stifel lowered the firm’s price target on Abbott (ABT) to $120 from $145 and keeps a Buy rating on the shares. High-level Q1 performance optics were “all basically in-line with our expectations,” but “under the hood”, multiple other, more-complex factors drove a move lower, the analyst tells investors in a post-earnings note. The new “comparable” 2026 revenue growth guidance is exactly in-line with the prior 6.5%-7.5% organic revenue growth view, but this new guidance range benefits from the exclusion of now-ended Structural Heart royalty revenues and the inclusion of Exact Sciences, the analyst noted.